CLDI — Calidi Biotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Calidi Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.14 | 0.372 | 1.95 | 9.59 | 5.6 |
| Net Total Receivables | — | — | — | 0 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2.74 | 0.786 | 4.3 | 10.2 | 6.26 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.585 | 1.09 | 5.34 | 3.8 | 2.46 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 3.39 | 2.6 | 10 | 14.2 | 8.86 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 26 | 43 | 10.2 | 9.5 | 3.94 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 26 | 43.4 | 18.3 | 12.6 | 5.1 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -22.6 | -40.8 | -8.23 | 1.53 | 3.76 |
| Total Liabilities & Shareholders' Equity | 3.39 | 2.6 | 10 | 14.2 | 8.86 |
| Total Common Shares Outstanding |